Biogen Inc., of Cambridge, Mass., said second-quarter revenues were about $3.682 billion, a 2% increase over the same period last year. Multiple sclerosis revenues, including $208 million in royalties on the sales of Ocrevus (ocrelizumab, Roche Holding AG), decreased 2% vs. the prior year to $2.3 billion. Spinraza (nusinersen) revenues increased 1% vs. the prior year to $495 million. Biosimilars revenues dipped 7% vs. the prior year to $172 million. Other revenues rose 155% vs. the prior year to $408 million, mainly due to about $330 million in revenues related to the license of certain manufacturing-related intellectual property to a corporate partner. Biogen estimates that its first-quarter 2020 product revenues benefited by about $100 million attributed to accelerated sales due to the COVID-19 pandemic, primarily in Europe, of which the company believes about $75 million was utilized in the second quarter of 2020. Second-quarter GAAP net income was $1.542 billion, and diluted earnings per share was $9.59. As of June 30, Biogen had cash, equivalents and marketable securities totaling about $5.3 billion. Shares of Biogen (NASDAQ:BIIB) closed July 22 at $280,81, up 62 cents.